Results
HCG Q2 Revenue Up 16% YoY, Sees Mid-High Single-Digit EBITDA Impact from Drug Margin Caps
HCG reported Q2 FY27 revenue of ₹7,318 million, a 16% YoY growth, driven by a 9% volume increase and 7% ARPP improvement.
Adjusted EBITDA grew 17% YoY to ₹1,425 million, with margins at 19.7%, moderat
